A 59-year-old woman received pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C. Her serum HCV RNA level was 980 KIU/m
l and genotype of HCV was 1b. Although her HCV RNA became undetectable 28 weeks after the start of the therapy, duration of the therapy was extended for 72 weeks because of the late viral response. Her HCV RNA reappeared 4 weeks after the end of the therapy. Although the level of HCV RNA increased to 2600 KIU/m
l 8 weeks later, it became less than 5 KIU/m
l 16 weeks later. Therefore, she was re-treated 3 times a week with 9 MU of consensus interferon. Since she remained negative for HCV RNA thereafter, the therapy was ended 24 weeks after its commencement. Finally, she obtained a sustained virological response.
View full abstract